Sign in

CMND on Nasdaq

Clearmind Medicine Inc.

Clearmind Medicine Inc. is a pharmaceutical preparations company based in Vancouver, listed on Nasdaq (CMND).1

Price unavailable

Last updated Oct 21, 2026.

Overview

Compare with another stock.

  • TickerCMND on Nasdaq1
  • IndustryPharmaceutical Preparations1
  • HeadquartersZ41
  • Incorporated inCanada (Federal Level)2
  • Business address101-1220 West 6Th Avenue, Vancouver, British Columbia, Z4 V6H1A52
  • Filer categoryNon-accelerated filer, Emerging growth company2
  • Legal formCorporation

See how the biggest companies compare on our leaderboards

101 – 1220 W. 6th Ave, Vancouver, BC V6H1A5. Our telephone number is 973.536.1016. Our website address is https://www.clearmindmedicine.com/ .3 From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Financial statements

Net income456-$3.9M in 2025+42% since 2021
-$10.0M-$7.5M-$5.0M-$2.5M02021: -$2.7M-$2.7M20212022: -$6.9M-$6.9M2022+153%2023: -$8.6M-$8.6M2023+25%2024: -$5.3M-$5.3M2024−39%2025: -$3.9M-$3.9M2025−27%

Every line of the income statement as filed: the last 3 fiscal years, latest first.6

Period ending2025-10-312024-10-312023-10-31
General and administrative (Note 18)$3.6M$4.4M$4.8M
Research and development, net (Note 19)$2.1M$1.4M$1.5M
Total operating expenses$5.7M$5.7M$6.3M
Changes in fair value of derivative warrant liabilities (Note 7)$1.1M$707.8K-$2.2M
Changes in fair value of short-term investments (Note 5)$844.5K-$68.6K-$107.6K
Foreign exchange gain (loss)$3.4K-$6.0K-$78.1K
Other finance expenses-$19.5K-$36.2K-$10.9K
Interest income on deposit$132.9K$271.2K$70.1K
Changes in fair value of convertible loans-$209.2K
Total finance income (expenses)$1.9M$868.2K-$2.3M
Dividend received$16.6K
Total other income$16.6K
Loss Before taxes-$3.8M-$4.9M-$8.6M
Tax expenses-$70.4K-$378.0K-$17.4K
Net Loss-$3.9M-$5.3M-$8.6M
Loss per share, basic (in Dollars per share)-$30.35-$67.80-$1,703.04
Loss per share, diluted (in Dollars per share)-$30.35-$67.80-$1,703.04
Weighted average number of shares for the purposes of basic loss per share (in Shares)127.1K shares77.5K shares5.1K shares
Weighted average number of shares for the purposes of diluted loss per share (in Shares)127.1K shares77.5K shares5.1K shares

Compare Clearmind Medicine Inc. with another company

Corporate structure

Clearmind Medicine Inc. sits at the top of its group. 1 entity on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of Clearmind Medicine Inc.

  • Iroquois Capital Management, LLC Filed SCHEDULE 13G/A on Clearmind Medicine Inc., latest Aug 12, 2026 (6 filings since Jan 22, 2024)
  • Capitalink Ltd. Filed SCHEDULE 13G/A on Clearmind Medicine Inc., latest May 15, 2026 (4 filings since Dec 1, 2025)
  • L.I.A. Pure Capital Ltd Filed SCHEDULE 13G/A on Clearmind Medicine Inc., latest May 15, 2026 (4 filings since Dec 1, 2025)
  • Nissim Daniel Filed SCHEDULE 13G/A on Clearmind Medicine Inc., latest Mar 9, 2026 (2 filings since Nov 28, 2025)
  • AdvisorShares Trust Filed SCHEDULE 13G/A on Clearmind Medicine Inc., latest Jul 3, 2025 (2 filings since Feb 14, 2024)
  • INTRACOASTAL CAPITAL, LLC Filed SC 13G/A on Clearmind Medicine Inc., latest Feb 6, 2024 (2 filings since Apr 14, 2023)
  • Eli Polatov Filed SCHEDULE 13G/A on Clearmind Medicine Inc., latest Dec 18, 2023 (2 filings since Oct 26, 2023)
  • XYLO TECHNOLOGIES LTD Filed SC 13G/A on Clearmind Medicine Inc., latest Sep 5, 2023 (2 filings since Feb 9, 2023)
  • SciSparc Filed SC 13G on Clearmind Medicine Inc., latest Dec 13, 2022
  • Clearmind Medicine Inc. Z4

Built from major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What Clearmind Medicine Inc. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Operating-lease assets (leased space)$17.4K6 Oct 31, 2025$51.7K6 Oct 31, 2024−66.3%

Investments

ItemLatestA year beforeChange
Cash and cash equivalents$3.9M6 Oct 31, 2025$6.6M6 Oct 31, 2024−40.3%

Intangibles and goodwill

ItemLatestA year beforeChange
Intangible assets, net (excluding goodwill)$97.4K6 Oct 31, 2025$108.3K6 Oct 31, 2024−10.1%

Leadership

Named in SEC Form D filings

People the company listed in its private-offering notices.

  • Executive OfficerAlan Rootenberg named Feb 7, 20247
  • Executive OfficerDr. Adi Zuloff-Shani named Feb 7, 20247
  • Executive OfficerProf. Mark Haden named Feb 7, 20247
  • DirectorAmitay Weiss named Feb 7, 20247
  • DirectorAsaf Itzhaik named Feb 7, 20247
  • DirectorOz Adler named Feb 7, 20247
  • DirectorYehonatan Shachar named Feb 7, 20247

Filings

369 filings to the SEC since October 2021: 6 annual reports, 5 insider forms, 25 large holders, 1 private raises, 332 other. The latest 20:

  1. Oct 13, 20266-K REPORT OF FOREIGN PRIVATE ISSUER EDGAR
  2. Oct 8, 20266-K REPORT OF FOREIGN PRIVATE ISSUER EDGAR
  3. Oct 7, 20266-K REPORT OF FOREIGN PRIVATE ISSUER EDGAR
  4. Sep 30, 20266-K REPORT OF FOREIGN PRIVATE ISSUER EDGAR
  5. Sep 23, 20266-K REPORT OF FOREIGN PRIVATE ISSUER EDGAR
  6. Sep 17, 20266-K REPORT OF FOREIGN PRIVATE ISSUER EDGAR
  7. Sep 14, 20266-K REPORT OF FOREIGN PRIVATE ISSUER EDGAR
  8. Sep 10, 20266-K REPORT OF FOREIGN PRIVATE ISSUER EDGAR
  9. Sep 8, 20266-K REPORT OF FOREIGN PRIVATE ISSUER EDGAR
  10. Sep 4, 20266-K REPORT OF FOREIGN PRIVATE ISSUER EDGAR
  11. Sep 2, 20266-K REPORT OF FOREIGN PRIVATE ISSUER EDGAR
  12. Sep 1, 20266-K REPORT OF FOREIGN PRIVATE ISSUER EDGAR
  13. Aug 24, 20266-K REPORT OF FOREIGN PRIVATE ISSUER EDGAR
  14. Aug 12, 2026SCHEDULE 13G/A EDGAR
  15. Aug 11, 20266-K REPORT OF FOREIGN PRIVATE ISSUER EDGAR
  16. Aug 6, 20266-K REPORT OF FOREIGN PRIVATE ISSUER EDGAR
  17. Aug 3, 20266-K REPORT OF FOREIGN PRIVATE ISSUER EDGAR
  18. Jul 30, 20266-K REPORT OF FOREIGN PRIVATE ISSUER EDGAR
  19. Jul 20, 20266-K REPORT OF FOREIGN PRIVATE ISSUER EDGAR
  20. Jul 17, 20266-K REPORT OF FOREIGN PRIVATE ISSUER EDGAR

The 369 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

5 open-market trades by officers, directors and large owners since October 2021: 1 buys and 4 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Jun 16, 2026HRT FINANCIAL LP10% ownerSale22,139$3.31$73.3KForm 4
Jun 15, 2026HRT FINANCIAL LP10% ownerSale3,183$3.32$10.6KForm 4
Jun 12, 2026HRT FINANCIAL LP10% ownerSale2,102$3.36$7.1KForm 4
Jun 11, 2026HRT FINANCIAL LP10% ownerSale225,191$0.12$27.0KForm 4
Jun 10, 2026HRT FINANCIAL LP10% ownerBuy2,159,052$0.15$323.9KForm 4

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Money raised

Private offerings the company reported to the SEC on Form D.

  1. Jan 11, 2024Raised $2.4 million in a private offering of equity Form D: 12 investors so far Form D

SEC filer profile

How Clearmind Medicine Inc. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARClearmind Medicine Inc.1
  • CIK0001892500
  • Filer statusNon-accelerated filer an emerging growth company; not a shell company3
  • Incorporated inBritish Columbia3
  • Fiscal year endsOctober 311
  • Industry code (SIC)2834 Pharmaceutical Preparations1
  • SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance1
  • Business address101-1220 West 6Th Avenue, Vancouver, British Columbia, Z4 V6H1A51
  • Phone972-54-57047491
  • Shares outstanding158,076 shares as of Jan 19, 20263
  • AuditorBrightman Almagor Zohar & Co., Tel Aviv, Israel PCAOB ID 1197; it also attests to the company’s internal control over financial reporting3
  • On EDGAR sinceDec 23, 20211
  • Filings369 in all: 6-K (204), CORRESP (26), EFFECT (23), UPLOAD (20), F-1/A (14), POS AM (14), SCHEDULE 13G/A (13), 424B5 (6)1
    All 28 form types

    F-1 (6), SC 13G (6), 20-F (4), 4 (4), 424B4 (3), DRSLTR (3), F-3 (3), SC 13G/A (3), SCHEDULE 13G (3), 20-F/A (2), DRS (2), DRS/A (2), 3 (1), 424B3 (1), 8-A12B (1), CERT (1), D (1), F-3/A (1), FWP (1), S-8 (1)

  • Latest filingsAnnual report (20-F) Jan 20, 2026

Securities registered for trading

ClassSymbolExchange
Common shares, no par value per shareCMNDNasdaq

From the cover page of the 20-F filed Jan 20, 2026 (Section 12(b) of the Exchange Act).3

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16